Vimarsana
Biggest News Aggregation in the World

Page 14 - Bridge Communications News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Bridge Communications. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Bridge Communications Today - Breaking & Trending Today

More New York runs, more destinations for Trans-Bridge Lines - Vimarsana News

More New York runs, more destinations for Trans-Bridge Lines

The Lehigh Valley-based bus company is adding service to New Hope, Flemington and Cape Liberty Cruise Port in Bayonne.

Intellia Therapeutics to Present Updated Interim Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Hybrid Congress 2023 - Vimarsana News

Intellia Therapeutics to Present Updated Interim Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Hybrid Congress 2023

Late-breaking presentation will include new safety, kallikrein reduction and attack rate data across all dose cohorts in the Phase 1 portion of the studyIntellia to host investor webcast on Monday,... | May 31, 2023

Decibel Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update - Vimarsana News

Decibel Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update

- Initiated CHORD™, a global Phase 1/2 dose escalation clinical trial of lead gene therapy product candidate, DB-OTO - - Announced approval from the U.K. MHRA and Spanish AEMPS for CTAs for... | May 15, 2023

Tenaya Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update - Vimarsana News

Tenaya Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

TN-201 Received Fast Track Designation from the FDA Dosing Complete in Phase 1 Clinical Trial of TN-301; Data Expected in Second Half 2023 Renowned Researchers Drs. Christine Seidman and Alex Marson... | May 10, 2023

Tenaya Therapeutics Receives FDA Fast Track Designation for TN-201 - Vimarsana News

Tenaya Therapeutics Receives FDA Fast Track Designation for TN-201

TN-201 Being Developed for the Potential Treatment of MYBPC3-associated HCM Dosing in Phase 1 Clinical Trial Expected to Commence in Q3 2023 SOUTH SAN FRANCISCO, Calif., May 02, 2023 -- Tenaya... | May 2, 2023